Gilead Sciences’ Veklury (remdesivir) is expected to be approved in the EU for treating COVID-19 in a matter of days after the European Medicines Agency today decided that the product should be granted conditional marketing authorization (CMA).
The EMA’s decision to recommend approval for the investigational drug was made during the June meeting of the agency’s drug...








